- Home
- PAVM vs CNTX Comparison
PAVM vs CNTX Comparison
Compare PAVM & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | CNTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1M | 47.7M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAVM | CNTX |
|---|---|---|
| Price | $2.11 | $0.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $36.50 | $4.14 |
| AVG Volume (30 Days) | 17.6K | ★ 1.0M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,000,000.00 | N/A |
| Revenue This Year | $132.39 | N/A |
| Revenue Next Year | $263.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.00 | N/A |
| 52 Week Low | $0.21 | $0.20 |
| 52 Week High | $43.99 | $3.62 |
Technical Indicators
Market Signals| Indicator | PAVM | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.25 | 21.37 |
| Support Level | $1.84 | N/A |
| Resistance Level | $6.56 | $0.36 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 16.49 | 0.00 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.